A Long-Term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Trial Profile

A Long-Term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 25 Nov 2014 New source identified and integrated (Clinical Trials Registry - India record, CTRI2009-091-000395).
    • 25 Nov 2014 New trial record
    • 20 Oct 2014 Results of a pooled analysis of extension trials NCT01104792 and NCT00839852 were presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top